Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

Laika B, Leucht S, Heres S, Schneider H, Steimer W.

Pharmacogenomics J. 2010 Feb;10(1):20-9. doi: 10.1038/tpj.2009.32. Epub 2009 Jul 28.

PMID:
19636338
2.

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.

Czerwensky F, Leucht S, Steimer W.

Ther Drug Monit. 2015 Apr;37(2):152-60. doi: 10.1097/FTD.0000000000000119.

PMID:
25090458
3.

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S.

J Clin Psychiatry. 2008 Sep;69(9):1416-22.

PMID:
19193342
4.

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.

Gunes A, Melkersson KI, Scordo MG, Dahl ML.

J Clin Psychopharmacol. 2009 Feb;29(1):65-8. doi: 10.1097/JCP.0b013e31819302c3.

PMID:
19142110
5.

Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.

Söderberg MM, Haslemo T, Molden E, Dahl ML.

Pharmacogenet Genomics. 2013 May;23(5):279-85. doi: 10.1097/FPC.0b013e3283602876.

PMID:
23492908
6.

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.

Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M.

J Psychiatr Res. 2008 Sep;42(11):884-93. Epub 2007 Dec 20.

PMID:
18086475
7.

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).

Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, Shibata N, Arai H.

Ther Drug Monit. 2008 Feb;30(1):35-40. doi: 10.1097/FTD.0b013e31816336fd.

PMID:
18223460
8.

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.

Park YM, Cho JH, Kang SG, Choi JE, Lee SH, Kim L, Lee HJ.

J Clin Pharm Ther. 2008 Feb;33(1):55-60. doi: 10.1111/j.1365-2710.2008.00872.x.

PMID:
18211617
9.

The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients.

Kootstra-Ros JE, Smallegoor W, van der Weide J.

Ann Clin Biochem. 2005 May;42(Pt 3):216-9.

PMID:
15949157
10.

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.

Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA.

J Clin Psychiatry. 2012 Aug;73(8):1077-86. doi: 10.4088/JCP.11m06916.

PMID:
22967772
11.

The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.

Lin YC, Ellingrod VL, Bishop JR, Miller DD.

Ther Drug Monit. 2006 Oct;28(5):668-72.

PMID:
17038883
12.

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.

Perera V, Gross AS, Polasek TM, Qin Y, Rao G, Forrest A, Xu J, McLachlan AJ.

Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1115-37. doi: 10.1517/17425255.2013.795540. Epub 2013 May 4. Review.

PMID:
23641727
13.

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.

Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, Osby U.

Eur J Clin Pharmacol. 2010 May;66(5):465-74. doi: 10.1007/s00228-009-0783-8. Epub 2010 Feb 9.

PMID:
20143052
14.

HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.

Ma X, Maimaitirexiati T, Zhang R, Gui X, Zhang W, Xu G, Hu G.

Int J Psychiatry Clin Pract. 2014 Oct;18(4):229-42. doi: 10.3109/13651501.2014.957705. Epub 2014 Sep 18.

PMID:
25152019
15.

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.

Gunes A, Scordo MG, Jaanson P, Dahl ML.

Psychopharmacology (Berl). 2007 Mar;190(4):479-84. Epub 2006 Nov 11.

PMID:
17102980
16.

Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.

Tybura P, Trześniowska-Drukała B, Bienkowski P, Beszlej A, Frydecka D, Mierzejewski P, Samochowiec A, Grzywacz A, Samochowiec J.

Psychiatry Res. 2014 Oct 30;219(2):261-7. doi: 10.1016/j.psychres.2014.05.039. Epub 2014 Jun 2.

PMID:
24930580
17.

Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population.

Boke O, Gunes S, Kara N, Aker S, Sahin AR, Basar Y, Bagci H.

DNA Cell Biol. 2007 Aug;26(8):527-31.

PMID:
17688403
18.

Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression.

Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS.

Int J Psychiatry Med. 2007;37(3):315-29.

PMID:
18314859
19.
20.

Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers.

Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E.

Mutat Res. 2005 Nov 10;587(1-2):59-66. Epub 2005 Sep 26.

PMID:
16188490

Supplemental Content

Support Center